Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating

Mizuho has increased its price target for Amgen (NASDAQ: AMGN) to $295 from $280, while maintaining an Outperform rating on the stock. This adjustment reflects continued positive sentiment from the analyst firm regarding Amgen’s financial prospects. The date of publication for this analyst action was February 10, 2026, at 10:07 am EST.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)